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Legislative dictates and societal expectations require a different ap-
proach to chemical safety assessment than has been used in the past
when extensive data were collected for only a handful of chemicals of
concern either to humans or the environment. Currently there is a
need to determine the potential biological effects of tens of thousands
of existing and new substances in a cost-effective and timely manner,
but resources for chemical testing currently are either static or decreas-
ing. Hence, there is increasing reliance on approaches to efﬁciently gen-
erate data concerning the possible biological activity of chemicals
through use of in silico models, in vitro assays, and short-term in vivo
tests emphasizing molecular and biochemical measures of effects
(National Research Council, 2007). This creates a challenge for effec-
tively translating results from these types of mechanistic/pathway-
based analyses into information useful to those ultimately responsible
for conducting chemical safety assessments.
The Adverse Outcome Pathway (AOP) conceptual framework was
developed to serve as a knowledge assembly and communication tool
to facilitate the transparent translation of mechanistic data into out-
comes meaningful to chemical safety assessment (Ankley et al., 2010).
Speciﬁcally, the AOP framework facilitates the identiﬁcation and evalu-
ation of causal linkages across biological levels of organization, such that
mechanistic responses can be reliably used in decision-making to pro-
tect from adverse effects, such as cancer in humans or suppression of re-
production of ecologically important species. Many regulatory agencies
across the world have recognized the potential of AOPs in supporting
more efﬁcient assessments of chemical safety. One notable example in-
volves the Organization for Economic Cooperation and Development(OECD). TheOECD initiated an international AOPdevelopment program
in 2012 that has sponsored and contributed to a number of critical activ-
ities, including the publication of standardized approaches for AOP de-
velopment and review, and the formation of an AOP-knowledgebase
(AOP-KB) to support AOP development and dissemination (Villeneuve
et al., 2014a, 2014b; Vinken et al., 2017). A critical motivation for
OECD involvement was the recognition by member countries that a
pathway-based approach to chemical safety can promote economic
growth aswell as the highest levels of health and environmental protec-
tion (Perkins et al., 2015).
As the AOP framework has evolved in the context of regulatory tox-
icology, it has become recognized that the potential stakeholder com-
munity is broader than those involved in chemical safety assessment,
as illustrated in Fig. 1. For example, the frameworkmay complement ac-
tivities to apply the tractability of mechanism-based approaches for ad-
dressing biomedical challenges (Benson, 2015; van Hasselt and van der
Graaf, 2015; Visser et al., 2014), in safety evaluations associated with
drug development (Mirams et al., 2014), systems toxicology (Stahl et
al., 2015) and clinical trial simulations (Han et al., 2016).
Our aimwith this paper is to present a strategic vision to help ensure
that the AOP framework can realize its full potential for multiple stake-
holder groups. The paper ﬁrst details the unique features and qualities
of the AOP approach and of the AOP framework, and goes on to proﬁle
a variety of stakeholders, describing how they stand to beneﬁt from
the further development of the AOP framework and its application to
solving their problems. Our analysis includes consideration of the core
obstacles to a full, long-termengagement of the stakeholder community
with the framework. Finally, we conclude with a set of recommenda-
tions regarding the steps that need to be taken to address these
Fig. 1. Stakeholders involved in the different areas of research and development in relation to AOP development and usage.
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tainable tool for the application of our scientiﬁc knowledge of living sys-
tems in numerous decision-making contexts.
This paper stems from a Pellston workshop held April 2–6, 2017 in
Cornwall, ON, Canada. The workshop was coordinated by the Society
of Environmental Toxicology and Chemistry (SETAC), and ﬁnancially
supported by multiple governmental and business organizations.
Pellston workshops typically assemble 30–40 (invited) experts on a
given topic in the environmental sciences, who are charged with deﬁn-
ing and proposing paths forward to address challenge(s) in the topic
area of interest. This Pellston workshop focused on a number of issues
associated with AOP science and implementation, including the devel-
opment of a “roadmap” to promote sustainable use of the concept. Spe-
ciﬁc needs addressed at the workshop were identiﬁed through a global
horizon scanning effort that gathered input from scientists and risk as-
sessors/managers from throughout the world (LaLone et al., 2017a). In
all, 41 experts representing government, academia and business, from
nine different countries in North America, Europe and Asia participated
in the workshop.
2. Features of the AOP framework and its AOP knowledge base
Over the past several decades the global scientiﬁc academic, phar-
maceutical, chemical and personal care product communities, as well
as government agencies, have invested billions of (US) dollars generat-
ing biological information. The goal has been both to extend basic scien-
tiﬁc knowledge of how biological processes causally unfold and to
inform the development of less harmful chemicals and more effective
disease diagnosis, prevention and treatment. Traditionally, this infor-
mation has been deposited in scientiﬁc publications, but the sheer num-
ber of papers, compounded by the fact that the information is often
conveyed in unstructured and inconsistent ways, makes it difﬁcult to
access, share and integrate. Initiatives to summarize and compile this
information into centralized data repositories have been only partially
successful, as they i) do not include all publications, ii) remain compart-
mentalized, and iii) use different ontologies. These disconnected data-
bases have resulted in the next level of “silo-ed” information. The rise
in bioinformatics, including collections of “omics” information and asso-
ciated relational databases, has also produced a vast amount of poten-
tially useful, but still ultimately difﬁcult-to-access information. An
additional complication is that lack of curation makes it difﬁcult to as-
sess the quality of much information (Tripathi et al., 2016; Lægreid
and Kuiper, 2015; Howe et al., 2008).The goal of the AOP framework is to compile and synthesize this
wealth of biological information such that it can be transparently and ef-
ﬁciently employed for decision-making. Fig. 2 provides an overview of
the AOP framework in the context of its potential application to the
translation and use of different types of data to support assessment of
the effects of chemicals on human health and the environment. The ini-
tial interaction of a chemical with a biological system is depicted as the
molecular initiating event (MIE), such as binding to a protein (e.g., re-
ceptors, enzymes) or DNA, or interactions with membrane lipids.
These MIEs can cause subsequent perturbations at higher biological
levels of organization, depicted as intermediate key events (KEs) along
an AOP, which ultimately may result in adverse apical responses such
effects on survival, reproduction, carcinogenesis, etc. In the case of eco-
logical assessments, impacts at the population level also often are an
endpoint of regulatory concern. Implicit in an AOP is that the depicted
KEs are causally-associated with one another via deﬁned KE relation-
ships, an attribute that can be assessed usingweight-of-evidence analy-
ses (Becker et al., 2015). It is this documented, formalized linkage across
biological levels of organization in anAOP that provides the basis for the
use of “alternative” data streams to predict the types of apical responses
deemed critical to regulations and risk assessments.
The AOP framework potentially goes beyond biological pathways,
but will improve our understanding of chemical toxicity in relation to
the ecological impacts of chemical contaminants in air, water, soil and
food as well as impacts to human health. Escher et al. (2017) give a de-
tailed account of how the mechanistic understanding of the AOP
framework can be useful beyond human health for broader ecological
issues. The AOP framework has wide implications for advancing the as-
sessment of chemical hazards across various environmental compart-
ments covering atmosphere, hydrosphere, biosphere, lithosphere, and
anthroposphere.
The AOP-KB also has speciﬁcally been designed to address the prob-
lem of unstructured and scattered information. The AOP-KB currently
consists of several software packages, all of which deal with collecting,
formatting and, to some extent evaluating, biological information. At
the time of writing, the AOP-Wiki is the most prominent and well-de-
veloped of the packages and therefore it is the illustrative focus in this
paper; however, the needs and issues for engagementwith the other el-
ements of the AOP-KB will likely be similar. The AOP-Wiki is an open-
source platform for collecting and organizing biological information.
At present the AOP-KB contains about 223 AOPs applicable to assess-
ments focused on both human health and the environment (http://
aopkb.org, accessed 20 Sep 2017). Other AOP-KB packages include
Fig. 2. Depiction of the role of the Adverse Outcome Pathway (AOP) framework in linking various data streams to outcomes relevant to regulatory decision-making for chemicals. MIE –
molecular initiating event, KE – key event, KER – key event relationship, AO – adverse outcome.
Source: From Ankley and Edwards (2018).
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(Table 1). A unique feature of the AOP-KB is that each of the modules
is being developed and managed by different agencies or entities, but
the overall organization and supporting documents are centralized
under the auspices of the OECD. It is not, however, the only database
for AOPs, since there will soon be a standard reporting template that
can be used to deposit AOPs in a network of interoperable databases
or knowledge bases, with the AOP-KB as a central hub.
Stakeholders need to be aware of all the unique features of the AOP
framework that make it worthwhile for them to fully embrace it and
motivate them to actively engage with the broader AOP community.
At its core, the AOP framework is a comprehensive means of gathering,
integrating, curating, sharing, reviewing and disseminating knowledge
about the mechanisms and consequences of perturbation of normal bi-
ological function by chemical or non-chemical stressors in different or-
ganisms. Ultimately there are three “selling points” of the AOP
framework, namely; i) the AOP knowledge itself, ii) the way the knowl-
edge is assembled/treated and iii) the potential applications and impact
the knowledge can have. The primary type of knowledge captured by
the framework is obviously related to toxicological processes andmech-
anisms. However, in a description of an AOP there is also valuable infor-
mation on test methods and models that can be used to measure or
predict the KEs that comprise an AOP, and information on chemicalTable 1
Components of the AOP knowledge base (KB) (http://aopkb.org/, accessed 20 Sep 2017).
Module Description Developing
entity
e.AOP.Portal Main entry point for the AOP-knowledge base
(AOP-KB)
OECD
AOP Wiki An open-source platform for collecting
and organizing biological information
US Environ
Ofﬁce of Re
Effectopedia An open-knowledge and structured
platform able to display quantitative
information on Adverse Outcome
Pathways (AOPs)
OECD
AOP Explorer AOP network visualization and analysis tool US Army C
Intermediate Effects Data
Base
Repository for key event information European C
Centreinitiators and their relevant chemical properties linked to the MIE.
Thus when one describes the type of knowledge covered by the AOP
framework, it is important to highlight the availability of information
on methods and chemicals associated with measurement of the KEs.
Some of the key attributes of the way knowledge is managed within
the AOP framework are depicted in Fig. 3(a). They include:
Clarity – the description of an AOP is highly structured and follows a
particular format and well deﬁned conventions and guidance
(Villeneuve et al., 2014a, 2014b; OECD, 2017, 2016a, 2016b, 2016c).
Once users become familiar with the format, it provides clarity, ease
and efﬁciency when accessing AOP knowledge and ultimately provides
a de facto reporting standard.
Synthesis – there is a wealth of existing knowledge relevant to
perturbedbiological pathways spread acrossmany sources. AnAOP typ-
ically captures knowledge froma large number of peer-reviewedpapers
and integrates and distills it into a concise form, resulting in consider-
able saving in time and effort for users.
Sharing – the framework is built with crowdsourcing and knowl-
edge-sharing very much in mind, not only for the initial development
of an AOP but also during ongoing reﬁnement and review. Since an
AOP covers many levels of biological organization, this naturally stimu-
lates and relies upon extensive collaboration across numerous scientiﬁc
disciplinesURL
http://aopkb.org/
mental Protection Agency
search and Development
http://www.oecd.
org/chemicalsafety/testing/adverse-outcome-
pathways-molecular-screening-and-toxicogenomics.
htm
https://www.effectopedia.org/
orps of Engineers https://github.com/DataSciBurgoon/aopxiv
ommission Joint Research aopkb.org
Fig. 3. An illustration of (a) the attributes of the AOP framework and (b) the potential applications of AOPs.
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viding ready access to AOP content. Further, with the anticipated adop-
tion of anOECDharmonised template for reporting AOPs and the recent
launch of the e.AOP.Portal (Table 1), it is possible to envision interoper-
able AOP platforms maintained by different parties across the world.
Transparency – AOP development and review processes are iterative
in nature and full transparency helps to engage potential contributors
directly, either as co-developers or reviewers, or indirectly through,
for example, the posting of comments on the AOP-Wiki discussion
pages. The identity of developers, contributors and reviews are also
displayed within the AOP-KB.
Quality – the quality of an AOP is assessed and assured through sev-
eral steps: the availability of detailed guidance for developers (OECD,
2017, 2016a, 2016b, 2016c), continuous crowdsourced peer review,
and curation by scientists involved in maintaining the AOP-KB. More-
over, AOPs developed within the context of OECD projects are subject
to two rounds of rigorous expert review, one by an OECD expert advi-
sory group, and the other by a panel of independent international
experts.
Endorsement – once an AOP has successfully passed through expert
review within the OECD process, it can be submitted to the Working
Party of National Coordinators for the Test Guidelines Programme and
the Working Party for Hazard Assessment for their collective endorse-
ment, leading ultimately to publication of the AOP in the recently cre-
ated series dedicated to AOPs (OECD, 2016c).
Quantiﬁcation – the description of anAOP can be enhanced by the in-
clusion of quantitative data, such as the dynamics underpinning KE re-
lationships (Villeneuve et al., 2014a; Wittwehr et al., 2017). In
addition, more complex processes can be represented through the
weighted combination of a set of interconnected AOPswithin a network
(e.g., LaLone et al., 2017b).
The AOP framework can be viewed by stakeholders from the per-
spective of its different potential applications (Fig. 3b). Some of these
are quite closely related, such as reducing animal testing, predictive tox-
icology and safety assessment. Essentially, AOPs provide a mechanistic
blueprint to design integrated assessment approaches based on combi-
nations of in vitro and in silicomethods that predict toxicological effects
of interest, thus reducing the need for animal testing (Tollefsen et al.,
2014). Moreover, including species-speciﬁc knowledge within AOPs
helps to address the increasing demand for species-relevant assess-
ments. Mechanistic proﬁling of molecular libraries during the drug de-
velopment process can be effectively informed by AOP knowledge to
guide the selection of appropriate batteries of in vitro high-throughput
screening (HTS) assays forﬁngerprinting the effects of chemicals to sup-
port their safety assessment. HTS bioassays can be employed to charac-
terise not only single chemicals but also be used to test complex
environmental samples in environmental monitoring (Schroeder et al.,
2016). By using concepts of mixture toxicity and effect-directedanalysis, it is even possible to relate the effects observed in the complex
environmental samples to known chemicals and to characterise the ef-
fects of mixtures of unknown chemicals (Brack et al., 2016; Neale et al.,
2015).
The AOP framework can also be described relative to current regula-
tory challenges and political concerns (Fig. 3b). Many agencies world-
wide are under pressure to identify and regulate endocrine disruptors
are looking to AOP-based approaches for hazard and risk assessment
that can help ﬁll data gaps within a reasonable timeframe, at an accept-
able cost, and keeping animal testing to a minimum (Coady et al., 2017;
Browne et al., 2017). The effects of “real-life” chemical mixtures repre-
sent another considerable challenge for risk assessors. In this context,
AOP networks could prove to be a vital tool to explore mixture effects
in order to focus attention on chemicals and AOPs that really matter
(Villeneuve et al., 2014a, 2014b). Finally, the safe substitution of hazard-
ous chemicals in products with less hazardous alternatives is an area of
growing importance, but the use of traditional toxicity testing methods
to inform the process are often too slow, ineffective and expensive.
Thus, AOP-based hazard proﬁling and ranking potential substitutes
based on their relative toxicity would be of great value tomany compa-
nies operating in a variety of sectors.
3. Stakeholders in the evolution of the AOP framework
The AOP approach cannot deliver on its full promise without a criti-
cal mass of stakeholders, representing different disciplines and sectors,
engaging it in different ways. There is a wide range of existing and po-
tential stakeholders in the framework (Fig. 1). In this section, we proﬁle
seven areas and four groups of stakeholders who are already engaged
(or could easily become more engaged) with the AOP framework.
Each proﬁle identiﬁes a typical community of stakeholders, outlining
why they are (or would be) interested in AOPs and how they could fur-
ther develop the framework. The list is not exhaustive or deﬁnitive but
ismeant to serve as an initial analysis of potential stakeholders and their
roles for the advancement of the AOP framework.
3.1. Regulatory assessment of chemical risks
A principal stakeholder group for the AOP framework and associated
knowledge consists of regulatory toxicologists, risk assessors and man-
agers directly involved in evaluating chemical safety and implementing
risk mitigation measures. The responsibilities and needs within this
group can be very diverse, depending upon jurisdiction, policy context
and legislative mandate. Regulatory toxicologists and risk assessors
have to deal with varied protection targets (e.g., various human groups
or facets of the environment), different hazard/risk assessment scenar-
ios, varying amounts of available data and/or levels of data collection ca-
pabilities (ranging from very little formost industrial chemicals, to large
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they are responsible (a few ranging up to thousands). Risk managers
then have to use the output of a risk assessment to make decisions on
whethermeasures should be taken as required by relevant laws and as-
sociated protection goals. Decisions might include restricting the use of
a hazardous chemical or requiring its prior authorisation, and often in-
clude consideration of socio-economic consequences of intervention,
which can be considerable. Accordingly, the utility and perception of
value of the AOP framework will vary for different members of this
stakeholder community. For example, assessors responsible for rapid
processing of large numbers of chemicals with limited data may rely
upon the AOP framework for the utilization of in silico and/or in vitro
data for hazard proﬁling, which would serve as the basis for identifying
chemicals of potential concern and prioritizing them for further testing
or assessment. This scenario is exempliﬁed by regulators involved in the
US Environmental Protection Agency's (EPA)'s endocrine disruptor
screening program, who use the AOP framework as a basis for prioritiz-
ing chemicals for possible in vivo testing based on their endocrine activ-
ity (Coady et al., 2017; Browne et al., 2017). Another scenario – such as
in pesticide risk assessment – may involve members of a stakeholder
group requesting the generation of new data, targeting tests/endpoints
most likely to be sensitive to a given chemical. In this case, AOP knowl-
edge can serve as a basis for guiding and optimizing test selection.
3.2. Chemical safety assessment for industry
The chemical industry is required to provide information for speciﬁc
apical endpoints relevant to human health and the environment to sup-
port safety assessments, as laid out under various regulations such as
TSCA in the US (https://www.epa.gov/tsca-inventory, accessed 20 Sep
2017), REACH Regulation in the EU (European Parliament, 2006), and
China REACH (Lau et al., 2012; Wang et al., 2012; CRS, 2014). These in
turn are supported by guidance documents outlining the acceptability
of methods concerning data requirements. These regulatory require-
ments are particularly relevant for companies involved in the develop-
ment of new chemicals/products, but can vary according to industry
sector (e.g., personal and homecare products, solvents, etc.). However,
there are also a number of other safety requirements within industry
that are driven by stewardship. These include identifying chemical al-
ternatives that have reduced environmental or human health impacts
(National Academy of Sciences, 2014), enhancing approaches for chem-
ical read-across and categorisation (chemical grouping and extrapola-
tion between chemicals), performing strategic/targeted testing (data-
gap ﬁlling), conducting biological read-across (interspecies extrapola-
tion), identifying non-animal approaches to safety assessment, and
conducting post-production environmental monitoring.
Perhaps the greatest contribution that an AOP-based approach can
provide to support regulatory toxicology and risk assessment is a reduc-
tion of the uncertainty in understanding hazardous effects for safety as-
sessment (and hence increased conﬁdence in the safety assessment)
through a better understanding of pathway plausibility and biological
read-across for targeted data-gap ﬁlling, etc. (Perkins et al., 2015). In
the short term the unique AOP construct allows information on KEs
and KE relationship-derived causal links from widely-varying data
sources (ranging from in silico to in vivo) to enable supporting weight
of evidence approaches to be used in, for example, biological read-
across, without the need for apical endpoint testing (e.g., Burden et al.,
2015).
In the mid to longer term, the AOP approach has the potential to be
used to help identify relevant pathways in the derivation of biological
pathway altering doses (Judson et al., 2011) or for helping to deﬁne bi-
ological points of departure (Bercu et al., 2016), as part of the risk as-
sessment paradigm shift outlined by the National Academy of Sciences
in the US (NAS, 2014). One high-proﬁle example of the use of AOPs in
chemical safety assessment in this forward-looking manner has been
in collating scientiﬁc data supporting an AOP for skin sensitization forthe purpose of assessing the risk of allergic reaction in humans without
the necessity of animal testing (Maxwell et al., 2014; OECD, 2012;
MacKay et al., 2013).
3.3. Product discovery and development
The pharmaceutical (both human and veterinary) and agrochemical
industries are primarily focussed on developing novel chemical entities
for the purpose of medicinal and agricultural usage. Here a requirement
is to efﬁciently identify compounds that may be harmful to human, an-
imal health or the environment. The motivations are signiﬁcant, as a
number of chemicals used, for example, in commonly prescribed medi-
cationsmay be hazardous to the environment (see reviewbyDaughton,
2003). A complementary need is the necessity to retain chemicals of
proven therapeutic effectiveness. There are a number of opportunities
to use the AOP framework to support these activities such as enriching
the triaging process identifying undesirable chemical/pharmacological
properties applied early in drug discovery to deprioritize chemicals
likely to cause harm. Secondly, AOPs from theAOP-KB could act as a pre-
cursor for onward,more quantitative approaches based on systems tox-
icology (Sturla et al., 2014) for simulating the potential consequences
on adverse outcomes that are still poorly characterised. For some
types of adverse effects such as hepatotoxicity (Woodhead et al.,
2017) and cardiac toxicity (Davies et al., 2016), there have already
been demonstrations of using in silico approaches in thepharmaceutical
industry. However, there is scope for extending consideration of these
toxicities in support of preclinical safety assessment of drug candidates
on sensorial systems, such as drug-induced disturbances on taste and
smell or sleep disorders (Cavero and Holzgrefe, 2015; Cavero and
Holzgrefe, 2017).Wider employment of the AOP framework to comple-
ment nascent approaches offers tangible beneﬁts in being able to enrich
the available chemistry for compounds that would be subsequently less
likely to fail due to unforeseen toxicities or environmental harm.
3.4. Medicine and health
The AOP framework would be enriched by the knowledge and ex-
pertise of clinicians, who could contribute understanding of the biolog-
ical and physiological context of AOPs, and therefore of their plausibility
or potential gaps. In turn, the AOP framework is applicable to under-
standing disease pathways across multiple biological levels and is a
highly useful addition to the “toolbox” of approaches increasingly
being used in the clinic for prevention, diagnosis and treatment, and
in biomedical and clinical research for drug discovery, efﬁcacy and
safety testing (Langley et al., 2015; EFPIA MID3 Workgroup et al.,
2016). Clinicians are important for fully developing the biomedical po-
tential of the AOP framework, as they could increase access to human-
based data (Rodriguez et al., 2015), and give a more contextualised un-
derstanding of in vitro assays. The framework could also offer unique
forms of support for clinicians using tools to ensure that prescribing is
optimised for the patient. To this end, a number of decision support sys-
tems exist to help the clinician better tailor prescribed medicines that
do not give rise to unintended adverse effects, such as co-medication
error. Longer-term ambitions may include decision support systems
that are tailored to individual patient characteristics beyond co-medica-
tions, such as diet, weight, sex and lifestyle. One such example is the
CredibleMeds database (Schwartz andWoosley, 2016), which provides
easy-to-use guidance to the clinician on the propensity for a particular
medication to cause proarrhythmia, particularly when there are predis-
posing genetic factors. Whereas decision support systems in clinical
contexts currently are largely based on statistical and epidemiological
correlations, the AOP framework and AOP-KB would augment decision
support by adding the layer of mechanistic data, making the biological
basis for outcomes more transparent. This development would ﬁt con-
sistently with the current aspiration towards Personalised Medicine
(e.g., pharmacogenomics), but would have to take heed of the
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mentation (Hedgecoe, 2004; Day et al., 2017).
The AOP framework also complements and supports the representa-
tion of disease progression, often referred to in medicine as the “natural
history of disease”. This might be particularly relevant to the identiﬁca-
tion of diagnosticmarkers of disease onset/progression,which could es-
sentially correspond to discrete KEswithin anAOP. Future development
would be particularly relevant for rare diseases, where progression is
often poorly understood (FDA, 2015). Given the maturity of the AOP-
based assessment for the likelihood of chemicals to cause skin sensitisa-
tion, this may substantiate the hope for further implementable system
for clinician decision support.
3.5. Environmental quality
Similar stakeholder groups as in chemical risk assessment are re-
sponsible for assessing the effects of chemical mixtures and complex
environmental mixtures in the environment- in water and in food.
Complex environmental mixtures pose a challenge that can be ad-
dressed more systematically through the application of AOP network
concepts (Villeneuve et al., 2014a, 2014b). In vitro bioassays increas-
ingly are being used for environmental monitoring to process many
samples in a time- and cost-effective manner. Recently it has been sug-
gested that in vitro HTS assays could provide water-monitoring pro-
grams focused either on human health (e.g., drinking water) or
ecological (e.g., efﬂuent discharge) effects (Schroeder et al., 2016). The
main criteria for an in vitro assay to be applicable for monitoring com-
plex environmental mixtures is that it sensitively detects chemicals of
environmental concern, and that it results in a measurement that can
be clearly related to relevant apical responses in organisms potentially
exposed to the contaminant mixtures (Fig. 4). The AOP concept there-
fore can serve as justiﬁcation for the choice of in vitro bioanalytical
tools (Escher et al., 2014; Neale et al., 2017). By anchoring in vitro
assay results (which typically reﬂect MIEs but in some cases also inter-
mediate KEs) to relevant AOPs, this information is provided efﬁciently
and, in turn, it is possible to develop new in vitro methods from knowl-
edge of environmentally relevant AOPs (Fig. 4).
3.6. Academic applications
Academic scientists currently involved with the AOP framework are
mostly human health and environmental toxicologists, biochemists,Fig. 4. Application of in vitro bioassays for environmental quality sumolecular and cell biologists, pharmacologists and bioinformaticians.
An example group of academics who have adopted the AOP concept
are environmental toxicologists, who have pursued different facets of
mechanistic research for many decades (Hermens et al., 1985; McKim
et al., 1987; van Welie et al., 1992; van Wenzel and Opperhuizen,
1995; Escher and Hermens, 2002), but with the advent of the AOP con-
cept were able to assemble this past work in the context of a unifying
approach and common language.
Academic researchers have dual incentives as stakeholders for the
AOP framework: i) they have vocational motivations as scientists who
aspire to advancing knowledge in their ﬁeld and teaching students;
and ii) they have career motivations. For the latter, publications are a
main indicator of scientiﬁc productivity and performance, and neces-
sary for career progression in terms of positions, resources, and promo-
tions. While there is some variability depending on country and
institutions, in general there is increasing pressure on academics to
demonstrate the impact of their research beyond academia. If the im-
portance of impact on policy-making and industrial innovation con-
tinue to grow, it could provide an important incentive to contribute to
AOP development.
Academic scientists are in a critical position to make a signiﬁcant
contribution to the uptake and establishment of the AOP framework
through training new generations of researchers and graduates who
will be employed in industry, policy and regulation. For example, aca-
demics are able to promote AOPs via course curricula and incorporating
the AOP-KB and applications in toxicology and pharmacology courses.
As exempliﬁed in a teaching monograph by Escher and Leusch (2012)
that heavily relies on theAOP framework, textbooks can greatly contrib-
ute to propagation of the AOP approach.
An example of engagement of academic stakeholders with the AOP
framework is the large European research consortium project SOLU-
TIONS (Brack et al., 2015), which has fully adopted AOPs as a unifying
concept to address the challenges related to identifying and assessing
water pollution. SOLUTIONS is an EU-funded research program with
the goal of developing tools for the identiﬁcation, prioritisation and as-
sessment ofwater contaminants thatmay pose risks both to ecosystems
and human health, to support the EU Water Framework Directive
(Brack et al., 2017; European Parliament and European Council, 2000).
SOLUTIONS relies heavily on the application of in vitro whole-organism
and cell-based bioassays within an AOP framework for assessing the ef-
fects of complex mixtures of aquatic contaminants (Altenburger et al.,
2015). Another prominent example of a major research consortiumrveillance monitoring that are anchored in the AOP framework.
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the EU Horizon2020 funded project, EU-ToxRisk (www.eu-toxrisk.eu).
The project aims to employ non-animal methods to develop new ap-
proaches to assessing the safety of chemicals in a variety of sectors, ad-
dressing in particular their potential chronic, developmental and
reproductive effects.
3.7. Non-governmental organizations (NGOs)
NGOs give voice to concerns emerging from civil society and to the
interests of those who are affected by chemical safety assessments
and resulting decisions. Apart from this common goal, individual
NGOs typically have differing, sometimes contrasting interests, and
therefore have different incentives for engagement. Despite this, they
are potential users of AOP knowledge and participants in developing
and using the AOP framework.
Engagement of the animal welfare NGOs stems from the desire to
move away from the use of animals for chemical evaluation and biolog-
ical research (Taylor et al., 2008). A companion concern is for improved
human and environmental health, but the main focus is on the animals
used in laboratories. Several animal welfare NGOs have recognized the
promise of AOPs, and are participating in and supporting their develop-
ment (see, for example, Sullivan et al., 2017) and promotion through
education, training, and dissemination (see Table 3). These NGOs are
also involved in promoting the AOP framework to the biomedical com-
munity (Langley et al., 2015, 2016).
As environmental NGOs' core mission is to foster environmental
protection, they are primarily concerned about the effects of chemicals
on humans and the environment. There is a strong public concern
about the large numbers of chemicals for which little safety information
is available. They are also concerned about perceived and potential
harm that is, or could be occurring via chemicals such as endocrine-ac-
tive substances, and potential developmentally-toxic or neurotoxic
chemicals (e.g., The Endocrine Disruption Exchange [TEDX], http://
endocrinedisruption.org/, last accessed 20 Sep 2017). Thus far, there
has been only a somewhat limited engagement of environmental
NGOs, with a few notable exceptions. Speciﬁcally, since pathway-
based information is used in research into the effects of pesticides on
the environment (Kongsbak et al., 2014; Zhu et al., 2018) it can be ex-
pected that thiswill increasingly be used in the analyses of environmen-
tal NGOs, and potentially they could both participate in building AOPs,
and beneﬁt from the development and use of AOPs. At the same time,
however, some environmental NGO groups have expressed concern re-
garding the scientiﬁc basis to the use of AOPs to support chemical safety
decisions and have questioned the independence and transparency of
the program at the OECD (Pesticide Action Network [PAN] EU, 2016).
Increased participation of environmental NGOs could help confront
these issues and facilitate their involvement in future developments.
4. Challenges to scaling up the AOP framework and its applications
Broad utilization of the AOP framework is dependent on involving a
criticalmass of stakeholders, whose participationwould ensure that the
framework reﬂects and co-evolves with their current and future needs.
There are a number of challenges in ensuring that the framework ade-
quately engages and continues to meet the immediate and long-term
needs of the different stakeholders proﬁled above; here we identify
some of these challenges and in the subsequent section recommend
cross-cutting strategies that can address different aspects of these chal-
lenges (see Table 2).
4.1. Formal publication versus providing input to the AOP-KB
Themost signiﬁcant hurdle for researchers for whom journal papers
are an important output is the status of the AOP-KB relative to formal
publication. Populating the AOP-KB currently requires considerablevoluntary effort, and the format is not necessarily compatible with the
content of peer-reviewed articles that are the basis for developing im-
pact metrics necessary for career advancement. Prior-publication rules
imposed by most scientiﬁc journals would preclude publication if the
information were already made available in the AOP-KB and, once pub-
lished in a peer-reviewed journal, researchers may have little incentive
to deposit their data in the AOP-KB. Potential copyright infringements
also may occur through uploading previously published material onto
the AOP-KB (such as the Wiki) (see Section 4.5 below).
4.2. Possible risks and burdens to stakeholders supporting the AOP
framework
While we take the view that the AOP framework is the most prom-
ising andmost realistic answer to the challenges of chemical safety test-
ing, it is necessary to highlight possible risks and burdens, so as to
address them.
Policy-oriented organizations (like OECD) play a critical role in sus-
taining the credibility of the AOP framework and in providing assurance
that AOPs can improve decision making. However, there are signiﬁcant
reputational risks, should there be non-optimal decision-making based
on AOP information or knowledge. This risk increases as the popularity
of the framework and the number of AOPs grow and the quality control
process becomes itself increasingly crowdsourced and not limited to a
tight community of highly dedicated scientists, as currently is the case.
Governmental and industrial organizations involved in safety as-
sessment are key players in securing the actual usefulness and hence
the ultimate success of the AOP framework. But they are also those fac-
ing themost serious risks in adopting them, since they could be held ac-
countable for harm to consumers, the environment or business
interests. There needs to be conﬁdence that decisions based on AOP
considerations are as good as conventional approaches.
Serious obstacles may come from lack of adequate incentives for de-
veloping and adopting new testing methods. For those in industry, the
pressures to deliver assessments to an existing regulatory standard
mean that there are few resources to consider alternative and new ap-
proaches.With signiﬁcant initial development costs required to demon-
strate robustness of a new approach, both in terms of intellectual and
ﬁnancial input, this means that often corporations are not in a position
to support signiﬁcant changes in an approach until it has already been
sufﬁciently vetted by other organizations. Regulatory agencies are also
resource- and time-strapped, such that adding another source of infor-
mation to be weighed against other types of scientiﬁc evidence can
make assessments more complicated.
4.3. Quality assurance
AOPs can serve a number of functions ranging from, at their most
basic, assembling available data as a basis for understanding what is
and what is not known about a given pathway, to relatively complete,
quantitative depictions of a pathway that could be applied to risk as-
sessment. Accordingly, Villeneuve et al. (2014a) describe a spectrum
of AOP development from “putative” to “quantitative”. Becker et al.
(2015) note that AOPs at all stages of this spectrum could be employed
for different applications, but users need to consider the degree of their
development and level of conﬁdence in a given AOP in the context of
whether it would be “ﬁt for purpose” for a given application. Basically,
the greater the impact of the application, the greater the conﬁdence re-
quired in a supporting AOP. This requires that there be a formal process
to assess AOP quality.
From a science point of view, the issue of quality control is tightly in-
terconnected with that of publication and peer review: the “gold stan-
dard” for quality assurance of research results. Accordingly, the AOP
community has established a multi-level system of reviewing well-de-
veloped AOPs, internally and externally. For example, OECD-endorsed
AOPs have a level of peer review equivalent or superior to that of a
Table 2
Multiple means for addressing the different challenges.
Publishing and review
strategy
Education and
training
Stakeholder speciﬁc
interaction
Translation into
application
Governance and funding
structures
Tensions between publication and knowledge base x x
Risks: ﬁnancial, reputational, etc. x x x
Quality control x x
Cross-disciplinary/sectoral understanding x x x
Ethical, legal and social issues x x x
Governance and sustainability x
1550 A. Carusi et al. / Science of the Total Environment 628–629 (2018) 1542–1556published paper. OECDendorsement is recognized as bringingwith it an
important reputational added value, especially by the regulatory com-
munity. Career wise for the academic community, there is still a prefer-
ence for publishing in known, and high impact journals, even though
they may recognise that the level of peer review is equivalent. The re-
view process is also an important way of building the AOP community,
as it draws in more contributors than those who develop and upload
AOPs. However, there is a question whether such a work-intensive pro-
cess can be sustained in the long term, especially in consideration of the
lack of incentives for some of the reviewers. An increasing number of
AOPs uploaded onto the AOP-KB would also make greater demands
on the pool of qualiﬁed, often over-committed reviewers.
4.4. Maintaining effective dialogue about the AOP framework among stake-
holder groups
The AOP framework originally arose from the discipline of ecotoxi-
cology to support regulatory decision-making (Ankley et al., 2010).
This means that collaborators in other ﬁelds may not necessarily be in-
terested in all its features, and may misunderstand aspects of the con-
cept, or ﬁnd the framework too constraining or simpliﬁed for their
ownneeds. A recent survey described by LaLone et al. (2017a) identiﬁed
a variety of concerns about AOPs, and attempted to address these using
a “frequently asked questions” approach. For example, an issue often
raised by researchers in biology, from academia and elsewhere, is the
perceived linearity of the AOP, which is a misconception.
Speciﬁcally, AOPs can be assembled into ‘non-linear’ networks
which at times can be a better reﬂection of reality and thus be a focus
of application (Villeneuve et al., 2014a, 2014b; LaLone et al., 2017b). It
must be noted however, that although these provisions in AOP develop-
ment allow for non-linarites and modulating factors to be included as
narrative in the description of an AOP, the AOP construct itself was
never intended to provide a means of representing a toxicological pro-
cess as a formalized (mathematical) dynamical systems biology type
model.
An important challenge in stakeholders dialogue arises because
of conﬂicting perceptions of the utility associated with different
levels of detail included in the AOP-KB. The tension between devel-
opment and communication in the AOP-KB is particularly prominent
for different stakeholder communities reﬂecting “users” as opposed
to “developers”, with the former often requiring less complexity
than the latter.
4.5. Ethical, legal and social aspects associated with use of the AOP
framework
There are legal issues around intellectual property rights (IPR) in the
production and dissemination of AOPs that deserve attention and ac-
tion. Since many scientists need ﬁrst to publish the results of their re-
search in academic journals, steps should be taken in order to enable
scientists to reuse their work for contributing to or authoring AOPs
without infringing on copyright ownership. Conversely, there is a
need to enable researchers to reuse parts of their research that have
been uploaded on the AOP-KB in publications without violating anti-plagiarism rules. In addition, AOPs published by theOECD do not specify
what kind of copyright, if any, protects the intellectual work and which
uses are authorised. This is strikingwhen intellectual work freely acces-
sible through the Internet often comes with clearly speciﬁed licences.
The same applies to what is available through the AOP Wiki, which by
its nature as a wiki platform, is often associated with open access and
free sharing or reuse of content. Authors need to have a clear perception
of the kind of IPR protection available forwork shared through the AOP-
KB.
AOPs are not only a tool for systematically organizing and curating
scientiﬁc knowledge and indicating knowledge gaps that need to be
ﬁlled, but have been promoted and are perceived as an important in-
strument for regulators dealing with protecting the environment and
human health. As such AOPs may be used in regulatory contexts where
the stakes and uncertainty are high, ﬁerce controversies may arise and
stakeholders may become polarized, as exempliﬁed by recent activism
around endocrine-disrupting chemicals in the EU (Le Monde, 2016).
An obvious ethical issue that AOP usage brings to the fore is the wide-
spread desire to reduce or ultimately replace animal testing for chemical
safety assessment. Asnotedabove, this is a strongmotivator for animalwel-
fare NGO stakeholders, but it may also result in tensions with other ethical
priorities, for example, associatedwithperceptions regarding the role of an-
imal tests in the effective protection of humanhealth and the environment.
The interplay and potential conﬂicts between these ethical priorities needs
further analysis.
The social aspects of AOPs are related to the fact that they can be
used by many different parties with different agendas and purposes,
and this could lead to misuses prejudicial for human or environmental
safety, or economically inefﬁcient and burdensome. Recent trends in
science policy and research funding emphasise that scientists need to
make an effort to foresee and prevent the misuse of their knowledge
and results (Ziman, 2001; Guston and Sarewitz, 2002; von Schomberg,
2007, 2013; Stilgoe et al., 2013), as is also evident in the European
Commission - Horizon 2020 (n.d.)- Science with and for Society pro-
gramme (https://ec.europa.eu/programmes/horizon2020/en/h2020-
section/science-and-society, accessed 20 Sep 2017). A robust consensus
about the appropriate conditions and domains of application of AOPs is
therefore needed. In other words, different stakeholders need to agree
on when (i.e., at what level of development) AOPs are ﬁt for what pur-
pose (e.g., prioritisation of chemicals for testing, to make a regulatory
decision, or for use as evidence in courts etc.; Becker et al., 2015). In
practice, this demands attention both to the production of knowledge
(making sure that AOPs meet high standards of epistemic robustness
and are not inﬂuenced by research susceptible to conﬂicts of interests
or biases) and to the translation and integration of that knowledge into so-
cial processes. Such integration also raises the question of how to deal with
incompleteness of scientiﬁc knowledge and whether and how to comple-
ment it with non-scientiﬁc knowledge dispersed in society (Funtowicz
and Ravetz, 1993; Nowotny et al., 2001; De Grandis, 2016).
4.6. Governance and sustainability
As the AOP framework continues to evolve, governance and coordi-
nation of the effort in the future would ideally involve all stakeholders
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best achieved through an impartial organization that broadly represents
the various stakeholder groups. This could be accomplished through a
dedicated professional society charged with coordinating advances in
AOP knowledge and communication for the common good of all. Cur-
rently, the Society for Advancement of AOPs (SAAOP; http://www.
saaop.org/, accessed 20 Sep 2017) handles several practical logistics as-
sociated with the wiki module of the AOP-KB, including funding an
open-access server, and providing support to ensure that information
supporting new or existing AOPs is entered into the system in amanner
consistent with established OECD guidelines. However, the SAAOP is
comprised of a comparatively small group of people, none of whom
are primarily dedicated to AOP-associated governance or coordination.
This is not a sustainable long-term situation.
Furthermore, to date, much of the investment in the basic AOP infra-
structure (e.g., key software in the AOP-KB, training, educational and
promotionalmaterials, etc.) has come via resources provided from a rel-
atively limited number of stakeholder groups, principally the US EPA
and the European Commission, often under the auspices of the OECD.
Since there is no assurance of continuing availability of resources from
these organizations, the development of a stable, long-term “business
plan” for provision of resources to cover these direct costs including
dedicated personnel needs to be deﬁned. Additionally, there needs to
be a formal vision to attract and involve other institutional investors.
5. Recommendations
Many challenges that have been discussed in the previous section
can be addressed in severalways. Solutions are proposed in this section;
however, there is not always a one-to-onemapping between challenges
and solutions. Instead, there are cross-cutting solutions to meet multi-
ple challenges (Table 2).
5.1. Publishing, depositing and reviewing strategies
The AOP framework is part of a rapidly changing publishing infra-
structure that is affecting almost all sciences (Clark, 2014). For example,
new data repository-oriented journals give rise to an opportunity to fa-
cilitate the process of integration between publication of AOPs in the
AOP-KB and in peer reviewed journals. In addition, many journals al-
ready allow supplementary information to be deposited in accredited
repositories, instead of as pdf ﬁles downloadable only from the journal's
website. A possible step forward would be to negotiate with publishing
houses the acceptance of the AOP-KB as a site for supplementary infor-
mation for published papers, in a manner analogous to the approach
used for genomic data archived in the NCBI GEO database (https://
www.ncbi.nlm.nih.gov/geo/, accessed 20 Sep 2017). For example,
those involved in AOP governance could discuss the possibility of mak-
ing deposits into the AOP-KB, or using the AOP framework standardized
format for depositing in other databases mandatory with the publica-
tion of AOPs in journals such as Environmental Science and Technology,
Environmental Toxicology and Chemistry and Toxicological Sciences, all
of which publish AOP-oriented papers. An example of how this can be
done is illustrated by Fay et al. (2017)whonote that “The examples pre-
sented in the following sections, …, are available in the AOP
knowledgebase …; AOP and KE numbers noted below reﬂect entries
within this database. For simplicity, KER numbers (direct and indirect)
are not displayed in the AOP ﬁgures; however, the web addresses for
each AOP and its corresponding KEs and KERs are provided in the Sup-
plemental Data.” There aremultiple beneﬁts to be gained from this inte-
grative model: the researchers get credit for their publications and
deposited data, the AOP data are openly accessible to peer-reviewers,
and the growth of the AOP-KB and related databases would be
accelerated.
Other possibilities in next generation publishing could include de-
veloping a database-only journal to complement the AOP-KB. There isan increasing trend towards database-only journals such as Molecular
Ecology Resources (Wiley, http://onlinelibrary.wiley.com/journal/10.
1111/(ISSN)1755-0998, accessed 20 Sep 2017) and Scientiﬁc Data (Na-
ture, https://www.nature.com/sdata/publish, accessed 20 Sep 2017) in
which the authors publish their work by depositing the research data
following a stringent format requirement, and provide detailed descrip-
tions of methods used for data collection, quality control and assurance,
processing and analyses. These database-only journals provide a new
framework for data sharing, thereby accelerating the pace of scientiﬁc
discovery. Such journals could be sponsored by technical societies
whose membership includes large numbers of AOP stakeholders, such
as the Society of Environmental Toxicology and Chemistry (SETAC) or
the Society of Toxicology (SOT).
Finally, it also might be possible to establish a journal whose main
focus is AOPs, though this could be perceived as a relatively narrow
ﬁeld of science thus limiting the number of contributors and hence
restricting its growth. Since the development of any new journal
would take time and resources, and obtaining an ISI Impact Factor can
take at least 3–5 years, this option could discourage academics from
submitting to an AOP-only oriented journal during its early develop-
ment phase.
For any of these solutions, it is paramount that the data format be
compatible and interoperable, so that information can be added onto
the AOP-KBwith minimum effort. Steps to ensure this are being under-
taken by the OECD.
5.2. Education and training: stakeholder-speciﬁc approaches and materials
Outreach to various stakeholder groups requires different strategies
and educational materials. Some common and overlapping characteris-
tics of stakeholders that will affect communication strategies include
whether they are AOP developers, users of AOP-based information, or
simply interested in understanding the concepts and the science behind
AOPs and their use. A list of existing guidance documents and training
presentations is available from SAAOP.org, but other centralized repos-
itories for this type of information are needed.
To date, most outreach has focused on scientiﬁc training of current
and potential AOP developers, and a number ofmaterials have been cre-
ated for this purpose (Table 3) Developers of AOPs need to understand
the history, background and potential uses of AOPs as well as informa-
tion concerning the AOP-KB. AOP developers also need detailed guid-
ance on collecting, organizing, naming and evaluating the data that
inform an AOP. There is a need to create greater awareness of the train-
ingmaterial that is already available, and constant effort needs to be di-
rected at creating suitable targeted material, and disseminating this to
pertinent stakeholders.
Finally, as university teaching evolves from learning content to mas-
tering problem-solving tools, the AOP concept offers an opportunity for
a structured approach to environmental toxicology and ecotoxicology.
Curricula may include practical courses on the development of AOPs
as team-building literature review courses or may apply the conceptual
framework of logic and uniform structuring of information. New venues
for spreading of AOP information that remain to be explored are the
emerging massive open online course (MOOC) that range from free
availability to formal inclusion into universities' curricula (Paton,
2014). At writing, the online training course AOP Wiki module is in
the process of becoming a certiﬁcation course, which could serve as
the ﬁrst version of an open online course.
5.3. Stakeholder-speciﬁc interaction
Different stakeholder communities have different needs regard-
ing how much information they require, how they prefer it pre-
sented, and how they most productively could interact with the
AOP-KB and approach. Research shows that virtual collaborative en-
vironments require signiﬁcant buy-in from the communities for
Table 3
Examples of existing AOP training material.
Source: (adapted from LaLone et al., 2017a).
Source Content
For developers
OECD Information about AOP Approach: http://www.oecd.
org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-and-toxicogenomics.htm;
Guidance documents: OECD, 2017, 2016a, 2016b, 2016c
European Commission Joint Research Center Background information on AOPs and AOP Wiki: https://eurl-ecvam.jrc.ec.europa.
eu/about-ecvam/networks-and-collaborations/adverse-outcome-pathways-aop
Human Toxicology Project Consortium (HTPC) and the Physicians
Committee for Responsible Medicine (PCRM)
Introductory PowerPoint presentations and videos available at https://humantoxicologyproject.
org/aops-101/
More in-depth video presentations about AOPs:
https://humantoxicologyproject.org/about-pathways/
or through the AOP Learning Channel
https://www.youtube.com/channel/UCeP-bYPc1CRD3Ieaqrl-ysg
HTPC Online AOP training course consisting of two modules, an introduction to AOPs and a tutorial on using the
AOP Wiki. Available for download from https://humantoxicologyproject.
org/about-pathways-2/aop-online-course/, or run directly from https://aopwiki.org/
For scientists
HTPC and PCRM Introductory PowerPoint presentations and videos available at https://humantoxicologyproject.
org/aops-101/
More in-depth video presentations about AOPs:
https://humantoxicologyproject.org/about-pathways/
or through the AOP Learning Channel
https://www.youtube.com/channel/UCeP-bYPc1CRD3Ieaqrl-ysg
HPTC AOP Online Course: https://humantoxicologyproject.org/about-pathways-2/aop-online-course/ or
https://aopwiki.org/
OECD Effectopedia Channel
https://www.youtube.com/channel/UCpAWpL0TS53rtPcwYvFC55Q
PCRM ‘Adverse Outcome Pathways: Path to Improved Chemical Tests without Animals’ http://www.pcrm.
org/AOPs
SETAC http://setac.sclivelearningcenter.com/index.aspx?PID=9484&SID=215605
National Centre for the 3Rs (NCRs) Pathways Based Approaches Resource Page:
https://www.nc3rs.org.uk/pathways-based-approaches-resource-page
US Environmental Protection Agency Adverse Outcome Pathways Research Brief:
https://www.epa.gov/chemical-research/adverse-outcome-pathway-aop-research-brief
For non-scientists
HTPC Toxicity 101 (text descriptions) (https://humantoxicologyproject.org/tox-101/)
1552 A. Carusi et al. / Science of the Total Environment 628–629 (2018) 1542–1556which they are designed, but this depends on a number of factors,
not least of which is the active participation of the communities in
designing and developing the interface of the knowledgebase
(Carusi and Reimer, 2010). The ‘build it and theywill come’ approach
does not work in engaging stakeholder communities. We recom-
mend participant-based approaches to usability studies and an iter-
ative approach to platform development, as this addresses two
issues at the same time: the usability of the interface for the different
communities, and their investment in its success through their par-
ticipation in developing it.5.4. Translation into application
Although AOP development principles are well described in guid-
ance documents (OECD, 2016a) and in the scientiﬁc literature
(Villeneuve et al., 2014a, 2014b; Fay et al., 2017), the actual develop-
ment of an AOP can be an extensive piece of work, equivalent to a sys-
tematic literature review. Case studies provide a very practical and
powerfulmeans of demonstrating the overall approach to AOPdevelop-
ment and are an ideal vehicle to engage and inform relevant parties,
ranging from potential scientiﬁc contributors to decision-makers inter-
ested in application. Case studies aremost illustrative when the context
in which the AOP is being developed is clearly described, together with
explanation of the process undertaken to assemble and weigh the evi-
dence (Fay et al., 2017; LaLone et al., 2017b; Horvat et al., 2017). Thus
good, impactful case studies demonstrate the process asmuch as the re-
sults. To the extent possible, case studies would beneﬁt from the activeinvolvement both of those developing and using AOPs/AOP KBs of
interest.
Case studies are also important to illustrate the application of AOPs
in different chemical risk assessment contexts (ECHA, 2016) and are
very complementary to general guidance (OECD, 2016b). For example,
the 12 case studies published by the OECD concerning ‘deﬁned ap-
proaches’ for determining the skin sensitisation potential of chemicals
(OECD, 2016c) illustrate how the knowledge captured in one AOP
(OECD, 2012) can provide themechanistic basis formany different solu-
tions to the same problem. Moreover, these particular case studies con-
tributed signiﬁcantly to the decision by EU regulators in 2016 to change
the standard information requirements under REACH (European
Parliament, 2006), requesting that in the ﬁrst instance chemicals be
assessed in terms of their potential to trigger KEs of the skin sensitisa-
tion AOP instead of conducting the standard animal test.
AOPs at different stages of development and backed by different
levels of evidence are ﬁt for different purposes (Becker et al., 2015).
For instance, an incomplete AOP with important gaps may be very use-
ful for a researcher interested in understanding which knowledge gaps
need to be ﬁlled, but not appropriate for regulatory applications. As a
tool facilitating the translation of scientiﬁc knowledge into regulatory
decision making and promoting the production of the knowledge
needed by regulators, the AOP-KB needs reﬂexivity in order to be re-
sponsive and responsible towards society. This means that the knowl-
edge made available to several stakeholders through the AOP-KB
should be presented so that each different group of stakeholders under-
stands and interprets correctly its level of robustness and suitability for
their own purposes. Reﬂexivity requires “being aware of the limits of
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not beuniversally held” (Stilgoe et al., 2013), and this demands that lim-
itations recognized by the author of an AOP should be conveyed to po-
tential users. It is important to work closely with stakeholders in
developing ways of presenting AOPs that provide themwith the neces-
sary information for using them appropriately. Considering that users
are not yet fully well-versed in using the AOP-KB, that misuses could
have a serious impact either on the environment or human health,
and that misuse leading to serious harm may discredit a novel tool
with great promise in the eye of the public, we suggest establishing a
translational surveillance exercise: an active monitoring of decisions
made on the basis of AOPs. The goal would be to promptly detect and
ﬂag up inappropriate uses that can have negative consequences for
safety and bring the AOP framework into disrepute. Moreover, this
would provide very useful feedback for improving the communication
strategy of the AOP-KB.
5.5. Governance and sustainability
Various alternatives are possible in terms of governance. While the
role of the SAAOP could be expanded to support a broader stakeholder
community, an alternative optionmight be to engage other professional
societieswith a stake in AOPs. For example, the SETAC and SOT arewell-
established scientiﬁc organizations representing a diverse membership,
many of whom already are stakeholders in the AOP community. There
would be a variety of mutual beneﬁts to establishing a governance
and coordination body for AOP-oriented activities through a multipar-
tite SETAC/SOT consortium of some type.
To ensure sustainability and advancement of the AOP framework,
adequate, ongoing ﬁnancial support is a prerequisite for continuity
and growth in the future. Currently, the AOP-KB (largely the AOP-
Wiki) platform is supported by membership fees (from the SAAOP).
While the OECD has funded the recent developments of Effectopedia
and the e.AOP.Portal, the technical support and input for development
of the AOP-Wiki are primarily contributed by volunteer experts. The
current, very restricted, funding model will hinder the further growth
of the AOP-KB, and even threatens its sustainability in its current form.
Continuous funding would be required to expand the IT hardware
(e.g., servers), and human resources, such as full-time personnel, to up-
grade software, enrich bioinformatics analyses, maintain the online sys-
tem and coordinate/organize promotion and outreach activities with a
view to supporting further growth of the AOP platform.
A critical role of a governance unit focused on AOPs would be devel-
opment of a formal Business Plan, for example, a multi-year AOP Devel-
opment Plan (ADP), presenting a sustainable ﬁnancial budget and
expense projections alongside with deliverables supporting the various
stakeholder communities. Based on this ADP, a governance unit should
be able to solicit resources from various potential funding agencies,
charitable trusts and donors. Our vision is that this unit would be a
non-proﬁt NGO (consistent with the current SAAOP model), which in
order to avoid potential conﬂicts of interest might impose a limitation
on sources of funding. For instance, to have a governance body sup-
ported only by industry or depending too much on the contributions
of one or a fewdonorswould be inappropriate and undermine indepen-
dence. Consequently, it would be important that contributions
supporting AOP development/systemmaintenance come from a variety
of contributors from different sectors, and that none can exercise undue
pressure on account of their relative ﬁnancial weight.
The GenBank (https://www.ncbi.nlm.nih.gov/genbank/, last
accessed 20 Sep 2017), which is an open access, annotated database
containing nucleotide sequences and their protein translations, could
serve as a model for AOP governance/support. Initial funding from
among others the National Institutes of Health, allowed for further col-
laboration with private enterprise. Early successes (Benton, 1990)
cemented a lasting partnership between central government and bioin-
formatics industry in funding the bank.Following theGenBank example, an AOP governance body could ini-
tially seek resources from multiple sources representing the whole
range of stakeholders and geographies. Since the AOP platform is an in-
ternational project, the funding may come from various countries. We
recommend that a nascent AOP Consortium consider development of
partnerships with the United Nations Environment Program (UNEP)
under their program for the Strategic Approach to International
Chemicals Management (SAICM). SAICM aims to promote chemical
safety around the world, and provides funding to support relevant pro-
jects. While funding is primarily directed to developing countries,
SETAC's long term history of collaboration with SAICM could provide a
good basis for exploring the possibility of getting support for the AOP-
KB in the context of the development of the “The Strategic Approach
and sound management of chemicals and waste beyond 2020”
(http://www.saicm.org/Meetings/FirstIntersessional/tabid/5463/
language/en-US/Default.aspx, accessed 20 Sep 2017).
Funding agencies at country or regional levels alsomay be interested
in supporting more targeted AOP endeavours. For example, the UK-
based National Centre for the Replacement, Reﬁnement and Reduction
of Animals in Research (NC3Rs) recently sponsored a call for proposals
on the development of an AOP for cardiotoxicity under their strategic
award funding scheme (https://www.nc3rs.org.uk/, accessed 20 Sep
2017). In the US, one could envision that various units within the Na-
tional Institute of Health could include similar disease or pathway-spe-
ciﬁc calls, or include contribution of information to the AOP Wiki as a
requirement for funding, in the sameway as the EU's Horizon 2020 pro-
gramme has provided funding to the EU-ToxRisk consortium, (which
includes a speciﬁc objective to develop AOPs for the KB).
In addition to OECD, UN and other international organizations and
private companies, support for the AOP framework might be sought
from charitable foundations and trusts. Prominent foundations like the
Bill andMelinda Gates Foundation, the Parker Foundation have funding
programs whose remit could include AOPs development; likewise sup-
port may be sought from, for instance, the PEW Charitable Trust and J.P.
Morgan.
5.6. Impact indicators
With the desire to create and maintain momentum for the develop-
ment, implementation and application of AOPs by stakeholders and to
support a plan to facilitate these actions, there is a need to understand
how successful the community has been at achieving its objectives.
Here we recommend key impact indicators to measure success. Our
criteria in selection of the key impact indicators are that they align to
the objectives and should be simple to adopt and measure. If we deﬁne
the overarching objectives of the strategy as i) to develop a sustainable
platform for the derivation of AOPs, ii) to engage and encourage stake-
holders in developing and using AOPs, and iii) to embed AOPs and
AOP thinking into decision-making we propose some initial “Impact In-
dicators” to measure success (Table 4). Additional Impact Indicators
may be adopted at later stages as the framework develops further.
6. Conclusion
Toxicological knowledge and regulation are currently at a turning
point; historical approaches to regulatory toxicology are no longer sci-
entiﬁcally, economically or socially robust enough to dealwith the chal-
lenges of assessing chemicals that affect the environment, human and
animal health. The AOP framework and associated knowledge has the
potential to make a signiﬁcant contribution to addressing these chal-
lenges, as well as parallel demands in biomedical ﬁelds. Realizing this
potential is a two-pronged process: the ﬁrst is to fully incorporate the
AOP framework into toxicological research and related scientiﬁc ﬁelds;
the second is to populate the AOP-KB with AOPs, making the constantly
evolving knowledge on AOPs consistently organised and curated, acces-
sible, shareable, and ﬁt for purpose in regulatory and other decision-
Table 4
Possible impact indicators to measure impact and success of the AOP framework and community initiatives.
Success
objective
Impact indicator What Timeline
1 Knowledgebase (KB)
metrics
Increase in the number of Wiki and webpage hits Baselining within 6 months + repeated
annually
Increase in the number of AOPs developed and in the KB Baselining within 6 months + repeated
annually
Increase in the number of OECD peer reviewed AOPs Baselining within 6 months + repeated
annually
Increase in the number of active users of the KB Baselining within 6 months + repeated
annually
Clear sustainable
governance and supported
platform
A deﬁned governance structure and an understanding of funding sources to provide
technical support
Within 1 year
2 Increase in biological
coverage
Increase in pathways and species AOPs Baselining within 6 months + repeated
annually
Publications Increase in publications related to AOPs Baselining within 6 months + repeated
biannually
Citations Increase in citations of AOP papers Baselining within 6 months + repeated
biannually
Altmetrics Increase in including (but are not limited to) citations on Wikipedia, discussions on
research blogs, mainstream media coverage, mentions on social networks such as
Twitter.
Baselining within 6 months + repeated
annually
Training and
communications
Increase in available online training materials and hits/uses of training materials. Baselining within 6 months and repeated
biannually
Uptake in
awareness/acceptance and
in formal training
Survey of awareness and use of AOPs focussed initially on key stakeholders, SETAC/SOT
members and establishments teaching toxicology courses (to include students).
Baselining within 6 months and repeated in
2 years.
3 Uptake in decision making Assessment of the number in use in regulatory submissions (REACH (European
Parliament, 2006) and PMN under TOSCA) and use in Investigational new drugs (IND)
applications
Assessment in 2 years of the number of
applications including AOPs over the
previous 2-year period.
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both stand to beneﬁt and to make signiﬁcant contributions to the AOP
approach, discussed the main challenges to full involvement with the
approach, and made far-reaching suggestions for a proactive, cohesive
and targeted approach to fully realizing the potential of the AOP
approach.
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